glp-1 agonist cardiovascular outcomes receptor agonists and cardiorenal in type 2 diabetes: an updated meta-analysis of eight CVOTs | Diabetology Human, exendin-based GLP-1 receptor agonists

doi: 10.1056/NEJMoa2032183 20 FoxCKAuerbachPBarrientos-PrezMGiesIHalePMMarcusCet al

Interestingly, the same group could demonstrate that treatment with Liraglutide at 10nM enhanced the migration capacity of hBMSC, suggesting context-specific effects of the drug beyond its influence on proliferation [21]

[DOI] [PubMed] [Google Scholar] 5.Nauck MA, et al

In a rodent model for obesity, tirzepatide administration induced a loss of body weight, by mechanisms of reducing food intake and by increasing energy expenditure (57)

doi: 10.1016/S0014-2999(00)00600-2

Their findings open up new possibilities for the development of new GLP-1 drugs (RSC